

See "Clinical features and outcomes in spontaneous intramural small bowel hematoma: cohort study and literature review" on page 135-143.

Supplementary Table 1. Clinical Characteristics and Outcomes of 4 Patients with Duodenal Involvement

No.	Age (yr)	Sex	Body weight (kg)	Underlying malignancy	Underlying illness except malignancy	Anticoagulant or antiplatelet	Chemotherapy regimen	Interval between diagnosis and chemotherapy (day)	Platelet count ($\times 10^3/\mu\text{L}$)	PT INR	aPTT (sec)	Length of fasting (day)	Length of hospital stay (day)
1	73	Female	61.8	AML	HTN, DM, CVA	None	Cytarabine, Idarubicin	9	66	1.16	51.8	5	27
2	68	Male	66.5	AML	None	None	Cytarabine, Idarubicin	62	28	1.1	30.6	3	5
3	77	Male	59.0	HCC, Pancreatic cancer	Liver cirrhosis, Pulmonary embolism	Low molecular weight heparin	Gemcitabine, Cisplatin	34	19	1.1	29.5	7	17
4	77	Male	72.1	None	HTN, Arrhythmia, CVA	Warfarin	None		221	17.8	120.0	3	11

AML, acute myeloid leukemia; HTN, hypertension; DM, diabetes mellitus; CVA, cerebrovascular accident; HCC, hepatocellular carcinoma.

Supplementary Table 2. Comparison of Characteristics and Outcomes Regarding Duration of Hospital Stay

Variable	Duration of hospital stay		P-value
	≤7 day	>7 day	
No. of patients	23 (62.2)	14 (37.8)	
Age (yr)	74.0±7.0	74.1±9.5	0.971
Male sex	15 (65.2)	4 (28.6)	0.045
Body weight (kg)	62.3±12.3	52.3±8.2	0.011
Underlying illness			
Hypertension	13 (56.5)	9 (64.3)	0.641
Arrhythmia	14 (60.9)	6 (42.9)	0.286
Cerebrovascular accident	5 (21.7)	8 (57.1)	0.039
Congestive heart failure	5 (21.7)	5 (35.7)	0.353
Coronary heart disease	5 (21.7)	2 (14.3)	0.687
Diabetes mellitus	6 (26.1)	2 (14.3)	0.683
Pulmonary or deep vein thromboembolism	3 (13.0)	1 (7.1)	>0.999
Heart valve replacement	1 (4.3)	2 (14.3)	0.544
Peripheral arterial disease	2 (8.7)	0	0.517
Malignancy	1 (4.3)	2 (14.3)	0.544
Charlson comorbidity index	4.2±1.7	4.9±2.3	0.246
Medications			0.497
Warfarin	18 (78.3)	8 (42.9)	
Aspirin	1 (4.3)	1 (7.1)	
Warfarin and aspirin	2 (8.7)	1 (7.1)	
Warfarin and clopidogrel	0	1 (7.1)	
Low molecular weight heparin	0	1 (7.1)	
Complaint at the time of presentation			
Nausea and/or vomiting	11 (47.8)	2 (14.3)	0.074
GI bleeding	7 (30.4)	7 (50.0)	0.234
Abdominal pain	16 (69.6)	8 (57.1)	0.443
Location of lesions			0.260
Duodenum	1 (4.3)	3 (21.4)	
Jejunum	11 (47.8)	5 (35.7)	
Ileum	11 (47.8)	6 (42.9)	
Initial laboratory findings			
White blood cell count ($\times 10^3/\mu\text{L}$)	14.8±6.3	9.9±4.6	0.017
Hemoglobin level, g/dL	12.5±3.1	10.0±2.5	0.016
Platelet count ($\times 10^3/\mu\text{L}$)	245.2±98.4	218.7±92.9	0.423
BUN level (mg/dL)	29.1±16.8	35.1±12.1	0.254
Creatinine level (mg/dL)	1.2±0.5	1.4±0.9	0.595
Albumin level (g/dL)	3.8±0.5	3.4±0.3	0.013
hs-CRP level (mg/dL)	6.0±5.9	5.2±4.5	0.660
PT INR	9.2±5.3	11.1±6.3	0.328
APTT (sec)	100.9±50.8	106.6±48.8	0.737
Length of fast (day)	2.2±1.4	5.3±5.6	0.057
Length of hospital stay (day)	3.9±1.9	18.4±16.0	0.005

Values are presented as number (%) or mean±SD.
hs-CRP, high-sensitivity CRP.